<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Osimertinib &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/osimertinib/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 16 Jan 2024 16:03:29 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Osimertinib &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Osimertinib Resistance and EGFR Mutations in NSCLC Treatment</title>
		<link>https://bioengineer.org/osimertinib-resistance-and-egfr-mutations-in-nsclc-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 16 Jan 2024 16:03:03 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[C797 mutation]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Drug resistance mechanisms]]></category>
		<category><![CDATA[EGFR mutations]]></category>
		<category><![CDATA[EGFR-TKI resistance]]></category>
		<category><![CDATA[Genomic analysis]]></category>
		<category><![CDATA[lung cancer]]></category>
		<category><![CDATA[Molecular oncology]]></category>
		<category><![CDATA[NSCLC]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Osimertinib]]></category>
		<category><![CDATA[T790M mutation]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[TKI combinations]]></category>
		<category><![CDATA[Treatment strategies]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=219366</guid>

					<description><![CDATA[The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein&#8217;s ATP binding site, overcoming resistance mechanisms. Analysis of circulating tumor (ct) [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">219366</post-id>	</item>
	</channel>
</rss>
